Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of July 2023, with a filing date of July 5, 2023. The document serves as a notice regarding the scheduling of the Company's 2023 Annual General Meeting of Shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is purely informational regarding corporate governance and does not contain financial statements.
Material Changes
No material financial changes versus the prior comparable period are reported in this document.
Guidance, Outlook, and Management Commentary
The Company announced the scheduling of its 2023 Annual General Meeting of Shareholders for Thursday, August 24, 2023, at 4:00 p.m. Israel time. The meeting will be held at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Tel Aviv, Israel. A Notice of the meeting is included as Exhibit 99.1.
Important Facts for Investors to Verify
- Verify the date and location of the 2023 Annual General Meeting (August 24, 2023, Tel Aviv).
- Confirm the registrant name is BiondVax Pharmaceuticals Ltd., as the input metadata referenced a different entity.
- Note that this filing contains no financial performance data or updated guidance.